PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
PacBio (PACB) has scheduled its fourth quarter 2024 financial results conference call for Thursday, February 13, 2025, at 4:30 pm Eastern Time (1:30 pm Pacific Time).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PacBio (PACB) has scheduled its fourth quarter 2024 financial results conference call for Thursday, February 13, 2025, at 4:30 pm Eastern Time (1:30 pm Pacific Time). Investors and interested parties can access the webcast through PacBio's investor relations website. For those preferring to dial in, toll-free and international numbers are available, and participants are advised to join ten minutes before the start time.
Details
News Market Reaction – PACB
The recorded move for PACB in the trading session of this news was -3.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time.
The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/.
Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 1-888-349-0136
International: 1-412-317-0459
If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q4 Earnings Call.”
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
ir@pacb.com
Media:
pr@pacb.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.